CliffBio
biologic

Tyenne

tocilizumab-aazg

Loss of exclusivity—loss of exclusivity
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand nameTyenne
Active ingredienttocilizumab-aazg
Strength200MG/10ML (20MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalMarch 2024
Marketing statusRx

More from Fresenius Kabi

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.